Intellia: FDA Accepts NTLA-5001 IND in Acute Myeloid Leukemia
16 Septembre 2021 - 2:16PM
Dow Jones News
By Colin Kellaher
Intellia Therapeutics Inc. on Thursday said the U.S. Food and
Drug Administration has accepted its investigational new drug
application for NTLA-5001 in acute myeloid leukemia, a cancer of
the blood and bone marrow.
The Cambridge, Mass., clinical-stage genome-editing company said
NTLA-5001 would be its first ex-vivo candidate using its
proprietary cell-engineering process for the treatment of cancer to
enter clinical studies.
Intellia said it plans to begin patient screening by the end of
the year for a Phase 1/2a study evaluating NTLA-5001 in adults with
persistent or recurrent acute myeloid leukemia who have previously
received first-line therapy.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 16, 2021 08:01 ET (12:01 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
